This firm is undervalued at 4.72 per share with modest projections ahead.
Omeros holds a
performance score of 10 on a scale of zero to a hundred. The company holds a Beta of 0.8706, which implies possible diversification benefits within a given portfolio. Let's try to break down what Omeros's beta means in this case. Omeros returns are very sensitive to returns on the market. As the market goes up or down, Omeros is expected to follow. Although it is vital to follow
Omeros current trending patterns, it is good to be conservative about what you can do with the information regarding equity existing
price patterns. Our philosophy towards forecasting
future performance of any stock is to look not only at its past charts but also at the business as a whole, including all fundamental and
technical indicators. To evaluate if Omeros expected return of 1.42 will be sustainable into the future, we have found twenty-eight different
technical indicators, which can help you to check if the expected returns are sustainable. Use Omeros
potential upside, and the
relationship between the
total risk alpha and
kurtosis to analyze future returns on Omeros.
The performance of Omeros in the marketplace will significantly impact your decision to invest in its stock. Revenue growth, profitability, competitive positioning, management quality, and industry trends can influence Omeros'
stock prices. When investing in Omeros, there are several factors to consider and potential outcomes to expect. As a company performs well, its stock price may increase, allowing investors to benefit from price appreciation. However, Omeros Stock can experience significant price fluctuations due to market conditions, economic factors, industry trends, or company-specific news. This is why investing in stocks such as Omeros carries risks, including the potential for capital loss. Stock prices can decline, and investors may incur losses if they sell shares at a lower price than their initial investment.
How important is Omeros's Liquidity
Omeros
financial leverage refers to using borrowed capital as a funding source to finance Omeros ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Omeros financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Omeros' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Omeros' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Omeros's total debt and its cash.
Omeros Gross Profit
Omeros Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Omeros previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Omeros Gross Profit growth over the last 10 years. Please check Omeros'
gross profit and other
fundamental indicators for more details.
What is driving Omeros Investor Appetite?
Omeros owns a total of sixty-two million seven hundred thirty thousand
outstanding shares. 30% of Omeros
outstanding shares are owned by
third-party entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulation than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or about to change. Please note that no matter how much assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
| 2022 | 2023 (projected) |
Interest Expense | 22.62 M | 18.58 M | Gross Profit | 33.76 M | 30.5 M |
Ownership Breakdown
| Retail Investors63.36% | | Institutions32.61% |
| Retail Investors | 63.36 |
| Insiders | 4.03 |
| Institutions | 32.61 |
Our take on Omeros small fall
Latest semi deviation is at 4.54. Omeros is displaying above-average volatility over the selected time horizon. Investors should scrutinize Omeros independently to ensure intended market timing strategies are aligned with expectations about Omeros volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Omeros' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Omeros' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
The Bottom Line
While many other companies in the biotechnology industry are either recovering or due for a correction, Omeros may not be as strong as the others in terms of longer-term growth potentials. To conclude, as of the 6th of March 2023, our ongoing 90 days advice on the enterprise is
Strong Hold. We believe Omeros is currently
undervalued with
average chance of financial distress for the next two years.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Omeros. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com